1st Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$535,563
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicaid Reimbursement Medicaid Rebates The Deficit Reduction Act of 2006: all provisions relating to prescription drug reimbursement Any other matter that relates to access to generic drugs Average Manufacture Price (AMP)/AMP Publication

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY New —
LISA LAYMAN —
JASON R MONEY —

Contacted: Food & Drug Administration (FDA); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); White House Office; HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Budget/Appropriations BUD

Generic Drug User Fees Funding for FDA, including by not limited to any proposal relating to funding for the Office of Generic Drugs FY2010 Presidential Budget Request FY2010 Congrssional Budget and Appropriations

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY New —
LISA LAYMAN —
JASON R MONEY —

Contacted: Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; Federal Trade Commission (FTC); SENATE

Trade (domestic/foreign) TRD

Free Trade Agreements, including but not limited to the Trans-Pacific Partnership FTA

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
JASON R MONEY —

Contacted: HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Federal Trade Commission (FTC); White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE

Copyright/Patent/Trademark CPT

Patent Reform, including but not limited to: S.515, S.610, and H.R.1260 Patent Settlements/Reverse Payments/Exclusionary Payments, including but not limited to: S.369 and H.R1706 Any other matter that relates to access to generic drugs

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY New —
LISA LAYMAN —
JASON R MONEY —

Contacted: SENATE; Congressional Budget Office (CBO); U.S. Trade Representative (USTR); White House Office; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC)

Bills named: S. 369 (111th), H.R. 1706 (111th), S. 610 (111th), S. 515 (111th), H.R. 1260 (111th)

Pharmacy PHA

Generic Biologics, including but not limited to: H.R.1427, H.R.1548, and S.726 Prescription Drug Safety Counterfeit Drugs/Import Safety/Pedigree, such as: H.R.759 Authorized Generics, including, but not limited to: S.501 and H.R.573 Prescription Drug Importation/Re-Importation Any other matters that relate to access to generic drugs

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY New —
LISA LAYMAN —
JASON R MONEY —

Contacted: Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); White House Office; SENATE; Congressional Budget Office (CBO); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 759 (111th), S. 726 (111th), H.R. 1548 (111th), S. 501 (111th), H.R. 573 (111th), H.R. 1427 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.